Press release
Deadline on Sept. 24th coming up in Lawsuit for Investors who lost money with MacroGenics, Inc. (NASDAQ: MGNX)
A Deadline is coming up on September 24, 2024in the lawsuit for certain investors in MacroGenics, Inc. (NASDAQ: MGNX).
Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and there are strict and short deadlines running. Deadline: September 24, 2024. MacroGenics, Inc. (NASDAQ: MGNX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On April 3, 2024, MacroGenics, Inc issued a press released describing a research abstract it submitted about the TAMARACK study. The press release summarized the research abstract's findings about Vobra Duo's safety profile, in which grade 3 events were under 32% for both doses and no deaths were reported.
On May 9, 2024, MacroGenics, Inc released updated safety and efficacy data for its cancer treatment study TAMARACK, which investigates the drug package "Vobra Duo." The Company announced Vobra Duo's adverse event rate was over 99% for both the 2.0 mg/kg and 2.7 mg/kg dosages and that adverse events grade 3 or greater were over 50% for both dosages. Five deaths were linked to the study. Analysts expressed surprise and dismay at the changes in Vobra Duo's safety profile relative to the announcements earlier in the year and questioned management's candor.
Shares of MacroGenics, Inc. (NASDAQ: MGNX) declined from $21.88 per share on March 06, 2024, to as low as $3.995 per share on June 20, 2024.
According to the complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges on behalf of purchasers of MacroGenics, Inc. (NASDAQ: MGNX) common shares between March 7, 2024 and May 9, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 7, 2024 and May 9, 2024, the defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine.
Those who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About:
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Sept. 24th coming up in Lawsuit for Investors who lost money with MacroGenics, Inc. (NASDAQ: MGNX) here
News-ID: 3660105 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for MacroGenics
Lawsuit filed for Investors who lost money with shares of MacroGenics, Inc. (NAS …
An investor, who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), filed a lawsuit over alleged violations of Federal Securities Laws by MacroGenics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 24, 2024. NASDAQ: MGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investigation announced for Investors who lost money with shares of MacroGenics, …
An investigation was announced for investors of MacroGenics, Inc. (NASDAQ: MGNX) shares over potential securities laws violations by MacroGenics, Inc.
Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by MacroGenics, Inc. regarding its business, its prospects and its operations were materially…
Type 1 Diabetes Market May See a Big Move | DiaVacs, XOMA Corp., Biodel, Macroge …
A Latest intelligence report published by AMA Research with title "Type 1 Diabetes Market Insights, Forecast to 2030" provides latest updates and strategic steps taken by competition along with growth estimates of market size. The Type 1 Diabetes Market report gives clear visions how the research and estimates are derived through primary and secondary sources considering expert opinion, patent analysis, latest market development activity and other influencing factors.
Free Sample…
Investigation announced for Long-Term Investors in shares of MacroGenics, Inc. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of MacroGenics, Inc.
Investors who are current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: MGNX stocks follows a lawsuit filed against MacroGenics, Inc. over…
Lawsuit filed for Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX)
An investor, who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), filed a lawsuit over alleged violations of Federal Securities Laws by MacroGenics, Inc..
Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2019. NASDAQ: MGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Rockvillem MD based MacroGenics, Inc., a biopharmaceutical…
Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroG …
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development.
Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc.
Download free report Sample at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis/report-sample
*Major companies…
